Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track GERN with free AI briefings, catalyst countdowns, and dilution alerts.

GERN · GERON CORP

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$337.5M Cash on Hand
364.2mo Cash Runway
Follow GERN by email Get an email when GERN reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about GERN, unsubscribe in one click. Privacy

📣 What GERN Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Imetelstat
FDA approved Jun 2024 · Rytelo
MDS (Myelodysplastic Syndrome) Phase 4 · NCT07939451 Not yet recruiting
GRN163L Breast Cancer Phase 1 · NCT00732056 Completed
Fludarabine Recurrent Childhood Acute Myeloid Leukemia Phase 1 · NCT06247787 Recruiting

Also used in these trials (approved or third-party drugs, not GERN's own candidates): Paclitaxel, Bevacizumab, Azacitidine, Hydrocortisone Sodium Succinate, Trastuzumab, Cytarabine, Leucovorin Calcium, Methotrexate, Ruxolitinib, Venetoclax.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

GERN holds $337.5M in cash and short-term investments (as of Sep 30, 2026) and burns about $2.8M/quarter from operations, an estimated runway of 364.2 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when GERN files for a raise →

👥 Who Owns GERN

Insiders 0.1% Institutions (326 holders) 75.5% Public and other holders 24.4%
HolderTypeShares% of sharesAs of
RA Capital Management, L.P. Institution (13G, 5%+) 66,502,728 10.32% 2026-06-30
Soleus Capital Master Fund, L.P. Institution (13G, 5%+) 41,508,659 6.44% 2026-03-31
Robert J. Spiegel
Director · +400,000 options
Insider 212,161 0.03% 2026-09-30
John A Scarlett
Chairman, President and CEO, Director · +2.87M options
Insider 137,500 0.02% 2025-02-27
James Ziegler
EVP, Chief Commercial Officer
Insider 100,000 0.02% 2025-02-27
Harout Semerjian
President & CEO, Director · +4.00M options
Insider 53,500 0.01% 2026-11-13
Scott Alan Samuels
EVP, Chief Legal Officer · +725,000 options
Insider 26,682 0.00% 2025-02-27
Michelle Robertson
EVP, CHIEF FINANCIAL OFFICER · +1.74M options
Insider 17,645 0.00% 2026-02-17
V Bryan Lawlis
Director · +180,000 options
Insider 13,300 0.00% 2025-05-09
Timothy Williams
EVP and Chief Legal Officer · +2.50M options
Insider 12,000 0.00% 2026-11-16
Ahmed ElNawawi
EVP, Chief Commercial Officer · +3.00M options
Insider 10,000 0.00% 2025-10-20

Share count 644,238,859 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full GERN picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for GERN and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.